This trial is testing a new drug for ALS. The drug will be given intravenously (through the vein) to people with ALS. The trial is open-label, meaning that everyone will know what drug they are receiving.
7 Primary · 5 Secondary · Reporting Duration: Blood samples collected predose to Day 5/6 after end of infusion on Day 1 and to EOS after Week 12 visit
24 Total Participants · 1 Treatment Group
Primary Treatment: ANX005 · No Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: